Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics

P. Todd Korthuis, Mary Jo Tozzi, Vijay Nandi, David A. Fiellin, Linda Weiss, James E. Egan, Michael Botsko, Angela Acosta, Marc N. Gourevitch, David Hersh, Jeffrey Hsu, Joshua Boverman, Frederick L. Altice

Research output: Contribution to journalArticle

Abstract

Background: Opioid dependence and HIV infection are associated with poor health-related quality of life (HRQOL). Buprenorphine/naloxone (bup/nx) provided in HIV care settings may improve HRQOL. Methods: We surveyed 289 HIV-infected opioid-dependent persons treated with clinic-based bup/nx about HRQOL using the Short Form Health Survey (SF-12) administered at baseline, 3, 6, 9, and 12 months. We used normalized SF-12 scores, which correspond to a mean HRQOL of 50 for the general US population (SD 10, possible range 0-100). We compared mean normalized mental and physical composite and component scores in quarters 1, 2, 3, and 4 with baseline scores using generalized estimating equation models. We assessed the effect of clinic-based bup/nx prescription on HRQOL composite scores using mixed effects regression with site as random effect and time as repeated effect. Results: Baseline normalized SF-12 scores were lower than the general US population for all HRQOL domains. Average composite mental HRQOL improved from 38.3 (SE 12.5) to 43.4 (SE 13.2) [β 1.13 (95% CI: 0.72 to 1.54)] and composite physical HRQOL remained unchanged [β 0.21 (95% CI: -0.16 to 0.57)] over 12 months follow-up. Continued bup/nx treatment across all 4 quarters was associated with improvements in both physical [β 2.38 (95% CI: 0.63 to 4.12)] and mental [β 2.51 (95% CI: 0.42 to 4.60)] HRQOL after adjusting for other contributors to HRQOL. Conclusions: Clinic-based bup/nx maintenance therapy is potentially effective in ameliorating some of the adverse effects of opioid dependence on HRQOL for HIV-infected populations.

Original languageEnglish (US)
Pages (from-to)S39-S45
JournalJournal of Acquired Immune Deficiency Syndromes
Volume56
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 1 2011

    Fingerprint

Keywords

  • HIV infections
  • buprenorphine
  • intravenous
  • opioidrelated disorders
  • quality of life
  • substance abuse

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Korthuis, P. T., Tozzi, M. J., Nandi, V., Fiellin, D. A., Weiss, L., Egan, J. E., Botsko, M., Acosta, A., Gourevitch, M. N., Hersh, D., Hsu, J., Boverman, J., & Altice, F. L. (2011). Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. Journal of Acquired Immune Deficiency Syndromes, 56(SUPPL. 1), S39-S45. https://doi.org/10.1097/QAI.0b013e318209754c